Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer

Luca Licata(Vita-Salute San Raffaele University), Giuseppe Curigliano(European Institute of Oncology), Federica Miglietta(University of Padua), Lajos Pusztai(Yale University), Carmine De Angelis(Baylor College of Medicine), Peter Schmid, Alessandra Fabi(Agostino Gemelli University Polyclinic), Giampaolo Bianchini(Vita-Salute San Raffaele University), Javier Cortés(Villa Maria Hospital), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Caterina Marchiò(Candiolo Cancer Institute), Maria Vittoria Dieci(Istituto Oncologico Veneto)
Cancer Treatment Reviews
May 16, 2024
10.1016/j.ctrv.2024.102762
Cited by 11

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k